Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

European Myeloma Researchers Seem Behind The Times

Home/European Myeloma Researchers Seem Behind The Times

European Myeloma Researchers Seem Behind The Times

Ouch! Another large myeloma drug study in the main auditoriam. The venue was full–over 4000 docs and clinitians–standing room only. Why? To listen to a Spanish study showing drug combination results with Velcade. Another damn melphalan/prednisone-based study! I need to pause here and ask you (and me!) to remember that European regulators seems far more strict than our FDA. (How is that possible?) The study compared melphalan/prednisone/Velcade with Thalomid and Velcade in different combinations. Surprise, surprise–Thalomid/Velcade did better in combo than melphalan/prednisone/Velcade. Bet you didn’t see that coming! Does Vegas or London have a betting pool on these studies? We all could have made some cash! One positive note: The overall survival rate for Thalomid/Velcade was “off the chart.” Again, this is a very limited chart showing 3 year survival. But the study concluded using the T/V combo as maintenance really works!

Back to work–next stop should be a good one–therapy updates in newly diagnosed young myeloma patients. Feel good and keep smiling! Pat